Pricing Log in Create free account
Saturday 17 October 2026 Export SNDX’s income statement to Excel — free account

Syndax Pharmaceuticals, Inc.

SNDX Healthcare Biotechnology

Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024. In the quarter to June 2026, revenue grew 91.8%, EPS grew 33.7%, free cash flow grew 65.5% and total debt rose 71.0%, each against the same quarter a year earlier.

12.88 0.77 −5.64%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−10.1×
Dividend yield
—
F-score
n/a
Altman Z
−2.09
Beneish M
3.29
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.75
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — 4 — — — 3 1 — — —
Insider Ownership 8.80%

Capital & Financial Ratios $m

Market Cap 1,220.00
Revenue 252.00
Net Income (220.76)
Free Cash Flow (220.87)
Net Debt 33.85
Current Ratio 6.77 (at or above 1.5: strong)
Debt/Equity 38.95 (above 2: weak)
P/E ratio 0.00
Fwd P/E (10.10) (negative: loss-making)
P/S ratio 4.55
P/B ratio 75.91 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 38.69% (at or above 15%: strong)
Next Y EPS Growth 59.55% (at or above 15%: strong)
Next Y revenue growth 82.24% (at or above 10%: strong)
Next 5Y EPS Growth 71.79% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.8×, against a ten-year median of 22.4×; over the ten years it ranged from −63.3× in 2016 to 594× in 2021.
P/S against its own 10 years 0.04%
10-year low 10-year high
P/B against its own 10 years 97.14%
10-year low 10-year high
EV/Sales against its own 10 years 5.99%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 578 583 414 554
Receivables — 11 68 70
Inventory — 0 33 33
Other — — — —
581 603 528 675
2023 2024 2025 Q'26
Payables 10 12 17 5
ST’ Debt — 12 — —
Other — — — —
58 104 120 100

Compound Annual Growth %

10y 5y 3y
Sales — 157.68% 384.33%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.31%) (23.84%) (48.29%)

Revenue $m

Mar Jun Sep Dec Year
’26 65 73 — — —
’25 20 38 46 68 172
’24 — 4 13 8 24
’21 0 0 12 127 140
’20 0 0 0 0 2
’19 0 0 0 0 2
’18 0 0 0 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (30) — — —
’25 (95) (88) (71) (69) (323)
’24 (84) (72) (62) (57) (275)
’23 (39) (35) (45) (41) (161)
’22 (42) (40) (29) (23) (134)
’21 (23) (24) (25) 101 29
’20 (16) (21) (18) (16) (71)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (30) — — —
’25 (95) (88) (71) (70) (323)
’24 (84) (72) (62) (57) (275)
’23 (39) (35) (45) (41) (161)
’22 (42) (205) (28) (23) (133)
’21 (23) (151) (25) 101 29
’20 (16) (21) (18) (16) (71)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.48) (0.55) — — —
’25 (0.98) (0.83) (0.70) (0.78) (3.29)
’24 (0.85) (0.80) (0.98) (1.10) (3.72)
’23 (0.59) (0.64) (0.73) (1.00) (2.98)
’22 (0.63) (0.62) (0.58) (0.62) (2.46)
’21 (0.54) (0.44) (0.40) 1.81 0.48
’20 (0.56) (0.42) (0.46) (0.44) (1.87)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 6.69 6.31 3.39 4.24 6.32 13.02 13.27 11.22 12.40 8.58

Analyst estimates 2026–2028

Powerpack
High 18.03 15.70 15.20 11.11 27.85 25.68 26.51 29.86 25.34 22.73
People
People Employees 33 44 38 35 43 59 107 184 270 298
Revenue/emp, $m 0.04 0.05 0.04 0.04 0.04 2.37 0.00 0.00 0.09 0.58
Income, $m
Income, $m Revenue 1 2 2 2 2 140 — — 24 172
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 0.00 — 96.51 95.96
EBT (44) (61) (74) (56) (73) 25 (149) (209) (319) (285)
EBT margin, % (3,645.25) (2,884.35) (4,875.48) (3,694.59) (4,822.54) 17.84 0.00 0.00 (1,346.11) (165.60)
Net income (44) (61) (74) (56) (73) 25 (149) (209) (319) (285)
Depreciation 0 0 0 (1) 0 1 (3) (15) (13) (11)
Per share, $
Per share, $ Revenue 0.08 0.10 0.06 0.05 0.04 2.68 0.00 0.00 0.28 1.99
Earnings (3.22) (2.90) (2.92) (1.84) (1.87) 0.48 (2.46) (2.98) (3.72) (3.29)
Cash flow (2.40) (2.26) (2.70) (1.66) (1.73) 0.56 (2.20) (2.28) (3.21) (3.73)
Capex (0.02) 0.00 (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (2.42) (2.26) (2.71) (1.66) (1.73) 0.56 (2.20) (2.28) (3.21) (3.73)
Book value 5.76 4.97 2.09 1.04 6.11 7.84 7.69 7.88 3.37 0.75
Shares, m 15 21 25 30 41 52 61 70 86 87
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 50.91 — — 0.00 0.00
P/S 87.72 87.35 74.43 176.47 605.60 8.16 — — 7.53 10.56
P/B 1.27 1.77 2.13 8.47 3.64 2.79 — — 3.93 28.16
EV/Sales 12.63 32.23 30.17 137.66 425.60 5.10 — — 5.94 10.29
EV/FCF (0.43) (1.43) (0.67) (4.11) (9.04) (7.31) — — (2.03) (5.49)
Cash, $m
Cash, $m Operating cash flow (35) (47) (69) (51) (71) 29 (134) (161) (275) (323)
Capex 0 0 0 — — 0 0 — — 0
Free cash flow (35) (47) (69) (51) (71) 29 (133) (161) (275) (323)
Balance, $m
Balance, $m Working capital 98 118 67 44 280 428 461 523 500 408
Total debt — — — 1 20 20 0 0 344 344
Net debt (105) (130) (81) (59) (273) (427) (484) (578) (239) (70)
Shareholders’ equity 84 104 53 32 252 408 467 554 288 65
Returns, %
Returns, % ROA (47.33) (49.39) (66.90) (76.02) (42.33) 6.64 (31.54) (37.72) (47.66) (45.50)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (434.21) 0.00
ROE 53.64 (64.53) (94.00) (132.43) (54.31) 7.55 (34.10) (40.98) (75.69) (161.82)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Syndax Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GHRS GH Research PLC $1.3B — (loss-making) — — n/m −66.62% (below 0%: shrinking) 0.00% 0.00% Compare
NKTR Nektar Therapeutics $1.3B — (loss-making) — (loss-making) −9.34% (below 0%: shrinking) n/m −65.73% (below 0%: shrinking) 100.00% (417.94%) Compare
SNDX Syndax Pharmaceuticals, Inc. $1.2B — (loss-making) — (loss-making) +91.76% (above 0%: growing) n/m +65.47% (above 0%: growing) 95.59% (54.95%)
DRTS Alpha Tau Medical Ltd. $1.2B — (loss-making) — — n/m −30.42% (below 0%: shrinking) 0.00% 0.00% Compare
TSHA Taysha Gene Therapies, Inc. $1.2B — (loss-making) — (loss-making) +206.77% (above 0%: growing) n/m −100.28% (below 0%: shrinking) 100.00% 0.00% Compare
LBRX LB Pharmaceuticals Inc $1.2B — (loss-making) — — n/m −579.03% (below 0%: shrinking) — 0.00% Compare
BCAX Bicara Therapeutics Inc. $1.2B — (loss-making) — — n/m −72.95% (below 0%: shrinking) — 0.00% Compare
DMRA Galecto, Inc. $1.2B — (loss-making) — — n/m −877.51% (below 0%: shrinking) 0.00% 0.00% Compare
VOR Vor Biopharma Inc. $1.1B — (loss-making) — — n/m −47.59% (below 0%: shrinking) 0.00% — Compare
Median of peers $1.2B — — — — −69.79% 0.00% 0.00%

All 614 Biotechnology stocks →

Syndax Pharmaceuticals, Inc. (SNDX) key facts

  • Strength: Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
  • Syndax Pharmaceuticals, Inc. (SNDX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SNDX traded at $12.88, a market capitalization of $1.2 billion.
  • Return on equity was −161.8% and debt-to-equity 38.95.
  • Its Altman Z-score is −2.09 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Syndax Pharmaceuticals, Inc. (SNDX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SNDX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com